Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
In what situations would you utilize radiation therapy for management of high grade urothelial carcinoma of the prostate?
Related Questions
In a patient with biochemical recurrence after radical prostatectomy for pT2 disease and a high-risk Decipher genomic classifier, with a PSA of 0.7 ng/mL, is there a rationale for administering salvage radiation therapy to the prostate fossa?
How would you manage a patient who developed an intraprostatic abscess after SpaceOAR injection, prior to starting radiation?
For patients starting Pluvicto, do you have patients stop their ARPI?
Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?
What are your institution's standard liquid intake instructions for prostate cancer patients going through definitive external beam radiation?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate-risk prostate cancer?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
Do you get DEXA scans routinely before starting ADT for prostate cancer or endocrine therapy for breast cancer?
